Related Experiment Video

Updated: Jul 16, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris

Samir Saha, Margareta Berglund, Christer Sylvén

    International Journal of Cardiology
    |February 27, 2007
    PubMed

    Insights

    Combination therapy with aspirin and clopidogrel significantly inhibits platelet aggregation more than aspirin alone. This finding applies to both patients with chronic stable angina pectoris and healthy individuals.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Hematology

    Background:

    • Chronic stable angina pectoris poses a significant cardiovascular risk.
    • Antiplatelet therapy, including aspirin, is a cornerstone in managing angina.
    • Dual antiplatelet therapy (DAPT) may offer enhanced efficacy.

    Purpose of the Study:

    • To compare the antiplatelet effects of aspirin alone versus aspirin plus clopidogrel.
    • To evaluate the efficacy of DAPT in patients with chronic stable angina pectoris.
    • To assess platelet aggregation inhibition in healthy controls receiving the same therapies.

    Main Methods:

    • A study involving 10 patients with chronic stable angina and 10 age-matched healthy controls.
    • Administration of aspirin (160 mg/day) and clopidogrel (300 mg loading, 75 mg/day).
    • Whole blood aggregometry performed at baseline and after 10 days using collagen or adenosine diphosphate (ADP) as stimulators.

    Main Results:

    • Both ADP- and collagen-induced platelet aggregation were significantly reduced (P<0.02) with combination therapy.
    • This enhanced inhibition was observed in both the angina patient group and healthy controls.
    • Combination therapy demonstrated superior platelet inhibition compared to aspirin monotherapy.

    Conclusions:

    • Dual antiplatelet therapy with aspirin and clopidogrel provides greater inhibition of platelet activity than aspirin alone.
    • This enhanced antiplatelet effect is consistent in both patients with stable angina pectoris and healthy subjects.
    • The findings support the use of DAPT for potentially improved outcomes in cardiovascular conditions.

    More Related Videos

    Microfluidics in Assessing Platelet Function06:47

    Microfluidics in Assessing Platelet Function

    Published on: November 8, 2024

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

    Published on: April 6, 2017

    Related Concept Videos

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Formation of the Platelet Plug01:22

    Formation of the Platelet Plug

    The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
    As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
    Antianginal Drugs: Nitrates and &#946;-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...